Granules India arm gets ANDA approval for colchicine capsules 

Madhu Balaji Updated - April 30, 2024 at 10:50 AM.

The wholly-owned subsidiary of Granules India has received Abbreviated New Drug Application (ANDA) approval from the US Food & Drug Administration (USFDA) for colchicine capsules, 0.6 mg.

The application was filed by Granules Pharmaceuticals, Inc. (GPI), a subsidiary of the company.

According to the stock exchange filing, the capsule is equivalent to ‘mitigare capsules’, 0.6 mg of Hikma International Pharmaceuticals LLC (Hikma).

Sign up for newsletters, unlock features and do more on The Hindu
LOG IN
Support our reporting.
SUBSCRIBE NOW

They are indicated for prophylaxis of gout flares in adults.

The stock rose 1.05 per cent to trade at ₹424.90 on the NSE as of 10.38 am.

Published on April 30, 2024 05:20
Tags

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
or read this article by Downloading TheHindu Businessline News app
If you're already a subscriber
Access just this article

TheHindu Businessline operates by its editorial values to provide you quality journalism.

Support our reporting.
Subscribe
This is your last free article.
to read unlimited content from TheHindu Businessline
Subscribe
Stay updated on Markets,Economy, Agri & more.
Get TheHindu Businessline News App on
Recommended Articles